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Abstract
Background: In 2002, 17.8% of the global cancer burden was attributable to infections. This study assessed the age-
standardized incidence and mortality rates of stomach, liver, and cervical cancer in Puerto Rico (PR) for the period 1992-
2003 and compared them to those of Hispanics (USH), non-Hispanic Whites (NHW), and non-Hispanic Blacks (NHB) in 
the United States (US).
Methods: Age-standardized rates [ASR(World)] were calculated based on cancer incidence and mortality data from 
the PR Cancer Central Registry and SEER, using the direct method and the world population as the standard. Annual 
percent changes (APC) were calculated using the Poisson regression model from 1992-2003.
Results: The incidence and mortality rates from stomach, liver and cervical cancer were lower in NHW than PR; with 
the exception of mortality from cervical cancer which was similar in both populations. Meanwhile, the incidence rates 
of stomach, liver and cervical cancers were similar between NHB and PR; except for NHB women who had a lower 
incidence rate of liver cancer than women in PR. NHB had a lower mortality from liver cancer than persons in PR, and 
similar mortality from stomach cancer.
Conclusions: The burden of liver, stomach, and cervical cancer in PR compares to that of USH and NHB and continues 
to be a public health priority. Public health efforts are necessary to further decrease the burden of cancers associated to 
infections in these groups, the largest minority population groups in the US. Future studies need to identify factors that 
may prevent infections with cancer-related agents in these populations. Strategies to increase the use of preventive 
strategies, such as vaccination and screening, among minority populations should also be developed.
Background
Infection with several viruses and bacteria has been asso-
ciated to the development of various cancer types [1].
Nearly 17.8% of the global cancer burden is attributable
to infectious agents [2], with a higher percentage in devel-
oping countries (26.3%) than in developed countries
(7.7%) [3]. The principal infectious agents associated with
cancer morbidity worldwide are Helicobacter pylori (H.
pylori) (5.5% of all cancers), human papilloma viruses
(HPV) (5.2% of all cancers), and hepatitis B (HBV) and
hepatitis C viruses (HCV) (4.9% of all cancers); these
agents account for 87.6% of the total cancer burden asso-
ciated to infections [2]. More specifically, between 74%-
78% of all stomach cancers worldwide have been attrib-
uted to infection with H. pylori, 85.4% of hepatocellular
carcinoma is attributable to HBV (54.4%) or HCV (31.0%)
infection [3], while persistent infection with certain types
of HPV has been established as a necessary cause for cer-
vical cancer, accounting for 100% of these tumors [2].
Moreover, HPV infection has been associated to cancer
of the vulva, vagina, penis, anus, oral cavity and orophar-
ynx [3]. Among other cancer types, bladder and nasopha-
ryngeal cancer, as well as various types of lymphomas and
sarcomas, have also been associated to other infectious
agents such as Schistosoma haematobium, Epstein-Barr
virus, HCV, H. Pylori, human T-cell leukemia virus type 1
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(HTLV-1), and human herpes virus 8 (HHS-8) [1,3-5].
Nonetheless, the percent of all cancers worldwide associ-
ated to these previously mentioned infections is less than
3% [3].
Worldwide, among infection-related cancers, stomach,
liver, and cervix uteri cancers not only account for the
vast majority of the total cancer burden associated to
infections [3,6], but they also have the highest incidence
figures [1]. Although the incidence of total cancer in
Puerto Rico (PR) is lower than that of the United States
(US), the incidence from infection-related cancers such
a s  s t o m a c h ,  l i v e r  a n d  c e r v i c a l  c a n c e r  i s  h i g h e r  i n  t h e
island than in the US, particularly among non-Hispanic
Whites (NHW). Contrary to the US, these cancer types
also rank among the leading cancer sites in incidence and
mortality in PR [7-12]. This pattern is similar to patterns
observed among Hispanics in the US (USH) who show
lower incidence and mortality rates from total cancer
than NHW for the most frequent cancer types, although
they experience a higher incidence of cancers related to
infectious agents [13-15], similar to that of their countries
of origin [16].
Information on the current burden of infection-related
cancers in PR and how it compares with other US racial/
ethnic groups is limited because these comparisons have
mainly focused on USH, NHW and non-Hispanic Blacks
(NHB) [14,15]. Understanding patterns of cancer inci-
dence in diverse racial/ethnic groups is essential to fur-
ther understand risk factors for disease occurrence in
specific populations and to direct appropriate cancer pre-
vention and control efforts for specific population sub-
groups. Thus, this study aimed to assess the age-stan-
dardized incidence and mortality rates of stomach, liver
and cervical cancer in PR and compared them to those of
USH, NHW, and NHB in the US for the period 1992-
2003.
Methods
Data sources
Incident cases and deaths for stomach, liver and cervical
cancer for all racial/ethnic groups were obtained from the
PR Central Cancer Registry (PRCCR) [17,18] and the Sur-
veillance, Epidemiology and End Results Program (SEER)
[19,20], respectively. The SEER program is a national can-
cer surveillance database that collects and reports inci-
dence and survival data from a sample of the US
population. The PRCCR is the fourth oldest population-
based cancer registry in the world [21] and collects infor-
mation on cancer in PR since 1951. The PRCCR is part of
the National Program of Cancer Registries (NPCR)
administered by the Centers of Disease Control and Pre-
vention (CDC). The PRCCR uses the coding standards of
the SEER and of the North American Association of Cen-
tral Cancer Registries (NAACCR); thus, the registry is
fully comparable with SEER data. In the year 2003, a CDC
audit concluded that 95.3% of all cancer cases diagnosed
or treated in hospital facilities in PR were appropriately
reported to the PRCCR; a result comparable to the US
median (95%) [22]. The third revision of the International
Classifica tion of Diseases for Oncology (ICD-O-3) was
used to select all cases diagnosed from stomach, liver and
cervical cancer between 2001 and 2003. Cases from 1992
to 2000, which were originally reported using ICD-O-2,
were converted to ICD-O-3. The specific codes for the
types of cancer studied were: cervical cancer (C53.0-
C53.9), cancer of the liver and intraepithelial bile duct
(C22.0-C22.1) and stomach cancer (C16.0-C16.9). Cancer
mortality data for PR and the US (NHW, NHB, USH) was
obtained, respectively, from the PRCCR as reported by
death certificates enacted by vital statistics from the
Puerto Rico Department of Health and from the SEER
program as reported by the National Center for Health
Statistics (NCHS). Causes of death were coded and classi-
fied according to the tenth edition International Classifi-
cation of Diseases (ICD-10). Mortality codes for the
specific types of cancer included: cervical cancer (ICD-9:
180.0-180.9, ICD-10: C53), cancer of the liver and intra-
epithelial bile duct (ICD-9:155.0-155.2, ICD-10:C22.0,
C22.0-C22.4, C22.7, C22.9) and stomach cancer (ICD-
9:151.0-151.9, ICD-10:C16).
Statistical Analysis
For each racial/ethnic group, annual age-standardized
incidence and mortality rates [ASR(World)] (per 100,000)
of stomach, liver and cervical cancer for 1992-2003 were
calculated, using the direct method (mortality rates were
based on underling cause of death) and the world popula-
tion as the standard [23]. To assess the trends in risk for
specific sites, the annual ASR(World) were calculated by
sex, as follows:   where wj is the
proportion of persons in the j-th age group of the stan-
dard population, dk
ij is the number of cases (new cases or
deaths) in the j-th age group for the i-th ethnic group in
the k-th year, and nk
ij is the population in the j-th age
group for the i-th ethnic group in the k-th year. The
annual percent change (APC) of the ASR(World) was
estimated using the joinpoint regression model [24]. The
Joinpoint Regression Program version 3.3 [25] was used
for the APC estimation using the following parameters: 1)
ASR World w i
k
j
j
dij
k
nij
k () =
= ∑
1
18Ortiz et al. Infectious Agents and Cancer 2010, 5:10
http://www.infectagentscancer.com/content/5/1/10
Page 3 of 10
logarithmic transformation of the rate, 2) zero joinpoint
model, 3) Poisson model using rate, 4) uncorrelated error
model, and 5) Hudson's method. To assess differences in
the incidence and mortality rates of stomach, liver and
c e rv i c a l  c a n c e r  b e t w e e n  P R  a s  c o m p a r e d  t o  t h e  o t h e r
racial/ethnic groups, the ASR(World) were grouped from
1999 to 2003 (averaged over the 5-year period). Then, the
standardized incidence ratio (SIR) and the standardized
mortality ratio (SMR) were estimated with 95% confi-
dence intervals [26], to compare the racial/ethnic risk
with PR as the reference group. W e also compared sex
differences in each racial/ethnic groups, with females as
the reference group, in the occurrence of stomach and
liver cancer. The STATA System release 10.0 (STATA
Corp, College Station, TX, USA) was used for the statisti-
cal analysis.
Results
Stomach cancer
Rates (1999-2003)
In men, the incidence rates (per 100,000) of stomach can-
cer ranged from 11.7 in NHW to 22.5 in PR; while in
women rates ranged from 5.5 in NHW to 12.9 in NHB.
NHW men and women had 48% (SIR = 0.52, 95% CI =
0.48, 0.57) and 50% (SIR = 0.50, 95% CI = 0.46, 0.55) lower
risk, respectively, of stomach cancer, than their counter-
parts in PR (Table 1). No significant differences in stom-
ach cancer risk were observed between USH and NHB
men and women as compared to PR, except for NHB
females who had a higher risk of the disease as compared
to women in PR (SIR = 1.17, 95% CI = 1.03-1.33). The
mortality rates (per 100,000) from stomach cancer in men
ranged from 6.8 in NHW to 17.1 in PR, and from 3.5 in
NHW to 8.7 in NHB in women (Table 1). NHW and USH
men and women had a lower risk of death than their
Puerto Rican counterparts (p < 0.05); whereas, no signifi-
cant differences in mortality were observed between
NHB and PR (p > 0.05; Table 1). In all racial/ethnic
groups, the incidence and mortality rates of stomach can-
cer were significantly higher among men as compared to
women (p < 0.05) (Table 1).
Trends
From 1992-2003, the incidence of stomach cancer
decreased 2%-3% per year in men and women from most
racial/ethnic groups, except for USH and NHB women
who showed relatively constant trends (Figure 1). Mean-
while, mortality showed a significantly decreasing trend
for women from all racial/ethnic groups (APC between 2-
4% for all groups) and a constant trend for men (Figure 2).
Liver cancer
Rates (1999-2003)
The incidence rates (per 100,000) of liver cancer in men
ranged from 7.0 in NHW to 14.2 in USH; and in women
from 3.0 in NHW to 6.4 in USH (Table 1). USH men had
a 20% (SIR = 1.20, 95% CI = 1.05, 1.37) higher risk of liver
cancer than men in PR. Whereas, NHW men and women
had 41% and 50% lower risk of liver cancer than PR men
and women, respectively. No significant differences (p ≥
0.05) in incidence rates were observed between NHB and
PR men; although NHB women showed a 29% (SIR =
0.71, 95% CI = 0.59, 0.85) lower risk of liver cancer than
PR women. Mortality rates (per 100,000) from liver can-
cer in men ranged from 6.9 in NHW to 13.6 in PR; and in
women from 3.3 in NHW to 7.8 in PR (Table 1). NHW,
USH and NHB men and women had significant lower
risks of death from liver cancer than men and women in
PR, ranging from 14% to 58% (p < 0.05) reduction in risk.
In all racial/ethnic groups, both the incidence and mor-
tality rates of liver cancer were significantly higher among
men as compared to women (Table 1).
Trends (1992-2003)
Although constant incidence trends (p > 0.05) were
observed in men and women in PR and in most of the
other racial/ethnic groups, the incidence trends of liver
cancer showed significant increases among NHW men
(APC = 2.0%), NHB men (4.9%) and NHW women (APC
= 2.1%) (Figure 1 and Figure 2). With respect to mortality,
the rates showed relatively constant trends (p > 0.05) for
all racial/ethnic groups, except for NHW women who
experienced an increasing mortality trend from liver can-
cer (APC = 0.9%).
Cervical cancer
Rates (1999-2003)
The incidence rates (per 100,000) of cervical cancer
ranged from 5.9 in NHW women to 12.7 in USH women.
Although no significant differences in cervical cancer
occurrence were observed between NHB and women in
PR, USH women had 40% (SIR = 1.40, 95% CI = 1.28,
1.53) higher risk of cervical cancer than women in PR
(Table 1). Whereas, NHW women had 35% lower risk of
cervical cancer than women in PR (SIR = 0.65, 95% CI =
0.60, 0.70). Mortality rates (per 100,000) of cervical can-
cer ranged from 2.1 in NHW women to 5.1 in NHB
women. No significant differences in mortality from cer-
vical cancer were observed between women in PR and
NHW. Whereas, USH women had a 41% and NHB
women had a 2-fold significant higher risk of death from
cervical cancer than women in PR (p < 0.05, Table 1).Ortiz et al. Infectious Agents and Cancer 2010, 5:10
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Table 1: ASR(World) for incidence and mortality (per 100,000) for stomach, liver and cervical cancer during 1998-2003.
Age Standardized Rate (ASR) Standardized Relative Ratio SRR (95% CI)
PR NHW USH NHB NHW/PR USH/PR NHB/PR
Incidence
Stomach
Male 22.53 11.71 20.13 20.22 0.52 (0.48-0.57) 0.89 (0.79-1.01) 0.90 (0.79-1.01)
Females 11.00 5.51 12.51 12.86 0.50 (0.46-0.55) 1.14 (1.00-1.29) 1.17 (1.03-1.33)
SRR Ma vs Fb 2.05 (1.82-2.30) 2.13 (2.02-2.25) 1.61 (1.42-1.83) 1.57 (1.38-1.76)
Liver
Male 11.89 6.96 14.23 12.20 0.59 (0.53-0.65) 1.20 (1.05-1.37) 1.03 (0.89-1.18)
Females 5.94 2.95 6.40 4.21 0.50 (0.44-0.57) 1.08 (0.91-1.27) 0.71 (0.59-0.85)
SRR Ma vs Fb 2.00 (1.72-2.33) 2.44 (2.27-2.61) 2.22 (1.92-2.59) 2.92 (2.46-3.27)
Cervix
Females 9.07 5.90 12.68 10.01 0.65 (0.60-0.70) 1.40 (1.28-1.53) 1.10 (0.99-1.23)
Mortality
Stomach
Male 17.07 6.75 11.76 16.01 0.40 (0.36-0.43) 0.69 (0.62-0.77) 0.94 (0.85-1.04)
Female 8.02 3.51 6.70 8.70 0.44 (0.39-0.49) 0.84 (0.74-0.94) 1.08 (0.97-1.22)
SRR Ma vs Fb 2.13 (1.85-2.45) 1.92 (1.88-1.97) 1.76 (1.62-1.90) 1.84 (1.75-1.92)
Liver
Male 13.59 6.86 11.73 9.88 0.50 (0.46-0.55) 0.86 (0.78-0.96) 0.73 (0.66-0.80)
Females 7.82 3.31 6.46 4.68 0.42 (0.38-0.47) 0.83 (0.73-0.93) 0.60 (0.53-0.67)
SRR Ma vs Fb 1.73 (1.51-1.99) 2.07 (2.03-2.12) 1.81 (1.68-1.96) 2.12 (1.99-2.22)
Cervix
Female 2.38 2.11 3.36 5.12 0.89 (0.76-1.04) 1.41 (1.20-1.68) 2.16 (1.84-2.55)
aMale
bFemaleOrtiz et al. Infectious Agents and Cancer 2010, 5:10
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Trends (1992-2003)
Significant decreases in the incidence trends of cervical
cancer were observed for women from all racial/ethnic
groups from 1992-2003, ranging from -2.2 for PR to -4.2%
for USH. Similarly, significant decreases in cervical can-
cer mortality were also observed for all groups, except for
PR where the decline was non-significant (p > 0.05) (Fig-
ure 2).
Discussion
Our study adds updated information to the previous
knowledge on infection-related cancers in PR as com-
pared to specific racial/ethnic groups in the US [7,10,11].
The higher incidence and mortality rates of stomach,
liver and cervical cancer observed among PR, NHB and
USH as compared to NHW are consistent with previous
studies in these populations [7,10,11,14]. Given the infec-
tious etiology of these cancers, these results might sug-
gest a higher prevalence of certain infectious agents
among these populations, and of the risk factors associ-
ated with these infections and neoplastic conditions.
Liver Cancer
Rates
Disparities in incidence rates of liver cancer among the
studied racial/ethnic groups are likely the result of varia-
tions in the distribution of risk factors in these popula-
tions, such HCV/HBV infection, genetics and
environmental factors or HBV vaccination coverage
[27,28]. The higher risk of liver cancer in men as com-
pared to women in PR and racial/ethnic groups studied is
consistent with previous data for PR [29,30] and the US
[14]. This has been explained by higher prevalence of risk
factors for liver cancer in men as compared to women
[31,32], such as higher alcohol consumption and HBV/
HCV infection [33-35]. In the US, the prevalence of HCV
in the general population ranges from 1.5% in NHW, 3.0%
in NHB [19] and 2.3% in PR [34]. Similarly, the prevalence
of HBV infection has also been shown to be greater for
NHB than for NHW [36]. Although data on HBV and
HCV for the USH population is scarce and may not accu-
rately reflect the true proportion of people infected [33];
a higher prevalence of HBV in the majority of Latin
American countries than in the US has been documented
[37], but data for HCV is very limited [38]. Although a
higher incidence of both HCV and/or HBV infection
among USH and PR than among NHW is difficult to doc-
ument, high risk behaviors for HCV infection, such as
drug use and needle-sharing are high in PR and among
NHB and USH [39,40]. In addition, lower HBV vaccina-
tion coverage has been documented for NHB and USH
children and adults in the US [27,28,34]. Finally, of special
interest are the significantly higher mortality rates from
liver cancer among men and women in PR compared to
USH, NHW and NHB. This result highlights health dis-
parities between the study groups, probably explained by
higher exposure to HCV/HBV , more advanced stage at
disease diagnosis, decreased access to effective therapies
a n d  o v e r a l l  a c c e s s  t o  ca r e  i n  P R  t h a t  w a r r a n t s  f u r t h e r
attention and research.
Trends
Our study showed relatively constant trends in the inci-
dence and mortality from liver cancer in PR, USH and
NHB; however, incidence trends among NHB men
increased. Increasing incidence and mortality patterns
were also observed among NHW men and women, a
result consistent with other studies in the US [41]. A pos-
sible explanation for the rising incidence of liver cancer
among NHW and NHB men is an increase in the preva-
lence of cirrhosis, mostly secondary to chronic infection
with HCV [41,42]. Also, the HCV cohort of patients
infected by intravenous drug use during the 1960's-1980
has been responsible for the increasing incidence trends
of liver cancer in the US [41,42]. In PR, despite the con-
stant trends in the incidence of liver cancer, it is expected
to increase in the next decades as a result of the projected
higher prevalence of HCV-related cirrhosis [42]. Mean-
while, the constant mortality trend in most study groups
s u g g e s t s  t h a t  n o  m a j o r  a d v a n c e s  i n  p r e v e n t i o n  a n d / o r
treatment of liver cancer have been achieved. For exam-
ple, no treatment has been proven effective in preventing
progression to chronic liver disease and HCC among
HBV carriers [6].
Stomach Cancer
Rates
The higher incidence of stomach cancer in PR compared
to NHW (although similar to that of NHB and USH) sug-
gests a higher prevalence of stomach cancer risk factors
in this population, including H. pylori infection as well as
other factors associated with infection, or other known
risk factors for stomach cancer such as a high intake of
salty foods and/or N-nitroso compounds [43-45].
Although data on the prevalence of H. pylori is scarce in
PR, infection rates with H. pylori are higher in NHB
(52.7%) and USH (61.6%) populations as compared to
NHW (26.3%) in the US [45]. This pattern supports the
higher incidence rates from stomach cancer among His-
panic populations in the US, similar to Latin American
countries [2,10,13]. These results suggest a higher burden
of H. pylori infection in PR, USH and NHB than in NHW,
thus, additional data in PR is warranted. Meanwhile, the
h i g h e r  ris k  o f  s t o m a c h  ca n c e r  i n  m e n  as  c o m pa r ed  t o
women in PR and in all racial/ethnic groups studied is
consistent with data for PR [29,30] and the US [14]. This
difference is explained by a higher prevalence of risk fac-
tors for this cancer in men as compared to women
[31,32], such as H. pylori  infection [33-35]. MortalityOrtiz et al. Infectious Agents and Cancer 2010, 5:10
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rates from stomach cancer were also significantly higher
for men and women in PR than for USH and NHW
(although similar to NHB). These differences might be
explained by differences in stage of disease at diagnosis,
decreased access to effective therapies and overall access
to care in PR and among NHB. These differences warrant
further attention and research. Among prevention strate-
gies, early eradication of H. pylori infection in high risk
patients (such as those of patients with peptic ulcer dis-
ease) should be promoted in PR, as this reduces gastric
cancer risk by reversing many biochemical, genetic and
epigenetic changes in stomach cancer induced by H.
pylori infection [46].
Trends
Decreasing incidence trends from stomach cancer
observed in our study are consistent to patterns observed
worldwide [6]. Although the reasons for these declines
are not well understood, they are thought to be related to
improvements in diet, food storage, as well as a reduction
in the prevalence of H. pylori infection caused by increas-
ing levels of living standards over the past 50 years and an
increased use of antibiotics [6,47,48]. The same could be
hypothesized for PR, given the improvements in living
conditions, education and sanitation [49]. In addition to
these factors, decreasing mortality trends may also be
explained by increased access to care in all population
sub-groups.
Cervical Cancer
Rates
The higher incidence of cervical cancer observed among
USH, NHB and PR could reflect a potential higher preva-
lence of HPV infection in these populations or lower
screening rates in these groups. Although no population-
based data for the prevalence of HPV have been reported
in PR that might explain the burden of cervical cancer
among women in this population, a high incidence of cer-
v i c a l  c a n c e r  h a s  b e e n  o b s e r v e d  i n  d e v e l o p i n g  L a t i n
American countries (33.5 per 100,000) and the Caribbean
(33.5 per 100,000) [50]. Although studies in the 1990's
suggested a higher prevalence of HPV in USH and NHB
in the US as compared to NHW [51], which support the
Figure 1 Trends for stomach and liver cancer among men in all racial/ethnic groups, 1992-2003.
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higher burden of cervical cancer in these groups, more
recent studies show a higher prevalence among NHB but
not among USH [52]. The higher incidence of cervical
cancer in these groups may also be influenced by the high
HIV/AIDS burden in these minority populations [53,54],
as cervical cancer is an important AIDS-defining illness
and may be the most common AIDS-related malignancy
in women [55]. Regarding mortality, PR and NHW had
similar risks of death from this malignancy, while USH
and NHB had increased risk. Disparities in cervical can-
cer screening compliance between these racial/ethnic
groups could also account for some of the observed dif-
ferences in both incidence and mortality. Nonetheless,
the lower prevalence of cervical cancer screening in PR
(70.2% in 1996, 73.3% in 2002) than in the US (84.7% in
1996, 87.2% in 2002) [35,56] and to those of the studied
racial/ethnic groups (>85%) does not support the lower
mortality from the disease in PR as compared to NHB
and USH.
Figure 2 Trends for stomach, liver and cervical cancer among women in all racial/ethnic groups, 1992-2003.Ortiz et al. Infectious Agents and Cancer 2010, 5:10
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Trends
Decreasing patterns of cervical cancer incidence and
mortality are consistent with data in PR [57] and the US
[58] and supported by the increased use of cervical can-
cer screening in these populations. Although they could
also be influenced by decreasing patterns of HPV infec-
tion in these populations, historical data of HPV infection
to support this hypothesis is unavailable. Nonetheless,
this is less likely given that infection with HPV is associ-
ated with high risk sexual practices, such as, early age of
sexual intercourse, multiple sex partners, and lifetime
number of partners; and in fact, high risk sexual practices
that have increased in younger cohorts [59].
Strengths and Limitations
This study provides updated population-based data on
the burden of infections-related cancers in PR compared
to racial/ethnic groups in the US. Among study limita-
tions, incomplete information regarding stage at diagno-
sis of cancer cases in PR limits our ability to consider the
impact of staging on cancer trends. Also, even though PR
is a Hispanic population, Hispanics in the US constitute a
heterogeneous group of persons from a variety of His-
panic origins that show substantial variability in cancer
rates [11]. Even though the Hispanic population residing
in the US described in our study is not directly compara-
ble to the Puerto Rican population living in PR, racial/
ethnic group comparisons identify disparities in the bur-
den of disease and generate hypotheses about the role of
environmental, genetic, social, and lifestyle factors on
cancer occurrence [7,60,61].
Conclusions
In conclusion, the higher overall burden of liver, stomach
and cervical cancer among PR, USH and NHB, as com-
pared to NHW, shows a health disparity between these
groups that could be explained by various factors: 1)
higher prevalence of infection with oncogenic infectious
agents in these racial/ethnic populations, 2) lower rates of
appropriate screening and early detection of cancer in
these groups, and 3) differences in access to advances in
preventive and treatment options among these popula-
tions. Nonetheless, the declining trends in the incidence
and mortality of stomach and cervical cancer in PR might
be explained by improvements in socioeconomic status,
reductions in the burden of infectious agents and
improvements in access to preventive and treatment care.
Further research is warranted to understand the observed
differences in cancer occurrence across these popula-
tions, with a particular focus on the burden of cancer-
related infectious agents in these populations and the fac-
tors associated with disease progression.
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